Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05232461 · ClinicalTrials.gov registry record · Phase 1

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

A Phase 1 study of Pharmacokinetics, sponsored by NeuroSense Therapeutics.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT05232461 is a Phase 1 study of Pharmacokinetics that has completed, run by NeuroSense Therapeutics. The registered enrollment target is 12 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05232461, a Phase 1 study of Pharmacokinetics, has completed, sponsored by NeuroSense Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, randomized, single-dose, three treatment, three-period crossover study comparing the test and reference products under fasted or fed conditions (as applicable). In one period of the study, PrimeC-ER tablets will be administered to subjects following an overnight fast of at least 10 hours. In a second period of the study, PrimeC-ER tablets will be administered to subjects at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In a third period of the study, a single 750 mg dose of ciprofloxacin and a single 200 mg dose of celecoxib will be co-administered to subjects following an overnight fast of at least 10 hours. The order of administration will follow a six-sequence randomization schedule. Blood samples will be collected at pre-dose and at intervals over 48 hours after dosing in each study period. Subjects will be confined at the clinical facility from at least 10.5 hours before dosing until 48 hours after dosing in each study period. The interval between doses will be at least 7 days. Subjects will return to the clinical facility 7 days (± 1 day) after the last study drug administration for an end-of study follow-up visit.

Conditions Studied

Pharmacokinetics

Interventions

  • DRUG PrimeC-ER 748 mg
  • DRUG Ciprofloxacin 750 MG
  • DRUG Celecoxib 200mg

Study Locations (1)

North Dakota

  • Novum - Fargo

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-04-08
Est. Completion 2022-08-30
Phase Phase 1

Sponsor

NeuroSense Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05232461

The ClinicalTrials.gov registry entry for NCT05232461 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (81% lower). The listed sponsor is NeuroSense Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 3 interventions - of which PrimeC-ER 748 mg is the first listed.

NCT05232461 reports 1 study location spanning 1 distinct geographic area - top geographies include North Dakota.

Frequently Asked Questions

What is clinical trial NCT05232461 about?

NCT05232461 is a clinical study titled "A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects". This is an open-label, randomized, single-dose, three treatment, three-period crossover study comparing the test and reference products under fasted or fed conditions (as applicable). In one period of the study, PrimeC-ER tablets will be administered to subjects following an overnight fast of at lea...

What is the current status of trial NCT05232461?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-04-08. Estimated completion is 2022-08-30.

What conditions does trial NCT05232461 study?

This clinical trial studies the following conditions: Pharmacokinetics.

What interventions are being tested in trial NCT05232461?

The interventions under investigation include: PrimeC-ER 748 mg (DRUG), Ciprofloxacin 750 MG (DRUG), Celecoxib 200mg (DRUG).

Who is sponsoring clinical trial NCT05232461?

This trial is sponsored by NeuroSense Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05232461 being conducted?

This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pharmacokinetics

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pharmacokinetics

All registered trials for this condition

North Dakota

All trials with a study site in North Dakota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.